Ablynx awaits regulatory decision

Ablynx NV experienced a net cash outflow of €26.2 million in the first quarter as it maintained a high level of research and development spending to support its portfolio of therapeutic proteins to treat inflammatory, oncology and respiratory diseases.

Full text available to subscribers only. Click here for information on subscribing to MedNous.